Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFT Annual Meeting & Food Expo In Brief

This article was originally published in The Tan Sheet

Executive Summary

Cantox expert advises on claim support: FDA's "competent and reliable scientific evidence" standard for structure/function claims appears less rigorous than its "significant scientific agreement" requirement for authorized or qualified disease-risk reduction claims, but is not actually so, regulatory consultant Kathy Musa-Veloso says. "Don't be deceived by this competent and reliable scientific evidence standard," she said July 19 at the Institute of Food Technologists Annual Meeting & Food Expo in Chicago. "In our view, it's really just a synonym for significant scientific agreement." Musa-Veloso, associate director of Cantox's Food & Nutrition Group, said even though industry stakeholders are surprised at the European Food Safety Authority's rejection rate for proposed nutrient claims, most structure/function claims in the U.S. likewise would be rejected (1"The Tan Sheet" June 7, 2010). FDA does not require firms to submit their products' structure/function claims for approval and clearly some product claims on the market are not substantiated. "If the food industry wants to encapsulate bioactives and claim efficacy akin to pharmaceuticals, [regulators] are expecting the same level of scientific data - robust clinical studies - which for the most part, do not exist," Musa-Veloso added during a session on health claims
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS104361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel